How Teplizumab Delays Type 1 Diabetes Onset
Teplizumab, a monoclonal antibody targeting CD3 on T cells, delays clinical type 1 diabetes (T1D) in at-risk individuals by modulating the autoimmune response. It binds to the epsilon chain of the CD3/T-cell receptor complex, partially activating T cells and inducing tolerance rather than full destruction of beta cells.[1]
Mechanism of Action on T Cells
Teplizumab engages effector T cells attacking pancreatic beta cells, triggering several immunosuppressive effects:
- Partial T-cell activation and exhaustion: It causes transient T-cell activation followed by anergy (unresponsiveness) and upregulation of exhaustion markers like PD-1 and TIM-3, reducing their beta-cell-killing activity.[2]
- Shift to regulatory T cells (Tregs): Promotes expansion of FoxP3+ Tregs, which suppress autoreactive T cells, restoring immune balance.[3]
- Cytokine modulation: Increases anti-inflammatory cytokines (IL-10, TGF-β) while decreasing pro-inflammatory ones (IFN-γ, IL-2), dampening the Th1-driven autoimmune attack.[1][2]
This preserves ~40-50% more beta-cell function compared to placebo, as measured by C-peptide levels.
Clinical Evidence from Trials
In the TN10 trial, a 14-day course of teplizumab delayed T1D diagnosis by a median of 2 years (from 24.4 to 48.4 months) in autoantibody-positive individuals with Stage 2 T1D (dysglycemia but not yet overt disease).[4] The PROTECT trial showed similar delay in new-onset Stage 3 patients, with sustained C-peptide at 18 months.[5] FDA approval in 2022 was based on these, marking the first disease-modifying therapy for T1D.
Who Qualifies and Treatment Details
Eligible patients are 8+ years old with ≥2 T1D autoantibodies, normal HbA1c, and dysglycemia (e.g., OGTT 2-hour glucose 200-250 mg/dL). It's a single 14-day IV infusion course (doses escalating from 51 μg/m² to 826 μg/m² daily).6 Retreatment efficacy is under study.
Duration of Delay and Limitations
Delay lasts 2-4 years on average, but varies; some patients remain diabetes-free longer.[4] It does not cure or prevent T1D—beta-cell loss resumes eventually. No head-to-head trials vs. other immunomodulators like rituximab exist.
Common Side Effects Patients Report
Rash (80%), lymphopenia (70%), headache (40%), and cytokine release syndrome (fever, nausea in first days). Most resolve post-infusion; monitoring includes CBC and liver enzymes.6 Long-term risks like infections or malignancy are rare in trials but tracked via REMS.
Sources
[1]: Herold et al., NEJM 2013
[2]: Daifotis et al., Sci Transl Med 2019
[3]: Ramos et al., Diabetes 2020
[4]: Herold et al., NEJM 2019
[5]: Herold et al., NEJM 2023